About Retrophin, Inc

Retrophin, Inc. is a privately-held New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis (FSGS), Duchenne Muscular Dystrophy and other catastrophic diseases.

The company's lead compound, RE-021,
 – more... 

Claim this company page
Headquarters
San Diego California, United States
Revenue
$28.2 Million
Employees
51 to 200
Industry
Links
Retrophin, Inc website